| Multiple Sclerosis |
1 |
1 |
| Health Care Facilities, Manpower, and Services |
0 |
0.98 |
| Outpatient Clinic |
0 |
0.24 |
| Social Determinants of Health |
0 |
0.21 |
| Adherence |
0 |
0.18 |
| Health Care Reform |
0 |
0.16 |
| Hospital |
0 |
0.16 |
| Patient Safety |
0 |
0.1 |
| Telehealth and Telemedicine |
0 |
0.1 |
| Food and Drug Administration (FDA) |
0 |
0.08 |
| House Call |
0 |
0.08 |
| Multiple Sclerosis Treatment |
0 |
0.99 |
| Adverse Effects |
0 |
0.04 |
| Attending Physician |
0 |
0.04 |
| Board Certification |
0 |
0.04 |
| Clinical Guidelines |
0 |
0.04 |
| Drug Reaction |
0 |
0.04 |
| Health Care Quality, Access, and Evaluation |
0 |
0.04 |
| Maryland |
0 |
0.04 |
| Multiple Sclerosis Relapse |
0 |
0.04 |
| Patient Counseling |
0 |
0.04 |
| Precision Medicine |
0 |
0.04 |
| Referral |
0 |
0.04 |
| Shared Decision-Making |
0 |
0.04 |
| Washington |
0 |
0.04 |
| Biologic Therapy |
0 |
0.03 |
| Genomic Medicine |
0 |
0.03 |